Montreal Heart Institute

Summary

Montreal Heart Institute is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Heart Failure, Atrial Fibrillation, Coronary Artery Disease, Heart Attack, Cardiovascular Disease and other specialties. Montreal Heart Institute is involved with conducting 220 clinical trials across 283 conditions. There are 21 research doctors associated with this hospital, such as Anita Asgar, Reda Ibrahim, MD, lena Rivard, MD, MSc, and Philippe Demers.

Top PIs

Clinical Trials running at Montreal Heart Institute

Heart Failure

Cardiovascular Disease

Type 2 Diabetes

Obesity

Coronary Artery Disease

Sarcoidosis

Ventricular Tachycardia

Arrhythmia

Cardiac Sarcoidosis

Bleeding

Multidisciplinary Screening

for Heart Failure

This trial uses a computer program to identify potential heart failure patients from medical records, followed by blood tests and AI heart imaging. It targets patients at risk of heart failure to catch the condition early. The process involves scanning records, testing blood for a specific marker, and using AI for detailed heart images if needed.

Recruiting

1 award

N/A

11 criteria

Heart Surgery

for Coronary Artery Disease

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy (STICH3C) trial is a prospective, unblinded, international multi-center randomized trial of 754 subjects enrolled in approximately 45 centers comparing revascularization by percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with multivessel/left main (LM) coronary artery disease (CAD) and reduced left ventricular ejection fraction (LVEF). The primary objective is to determine whether CABG compared to PCI is associated with a reduction in all-cause death, stroke, spontaneous myocardial infarction (MI), urgent repeat revascularization (RR), or heart failure (HF) readmission over a median follow-up of 5 years in patients with multivessel/LM CAD and ischemic left ventricular dysfunction (iLVSD). Eligible patients are considered by the local Heart Team appropriate and amenable for non-emergent revascularization by both modes of revascularization. The secondary objectives are to describe the early risks of both procedures, and a comprehensive set of patient-reported outcomes longitudinally.

Recruiting

1 award

N/A

4 criteria

Ziltivekimab

for Heart Failure and Inflammation

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.

Recruiting

1 award

Phase 3